Advancing Regenerative Medicine

We are committed to developing innovative solutions that enhance clinical outcomes while reducing the overall cost of healthcare. In addition to our current product offering, we have a robust development pipeline and are focused on developing the next generation of products derived from the placental tissues. We have over 25 patents applications filed with respect to our novel products, our proprietary processing techniques and the clinical use of our products as we seek to become the industry leader in this market segment.

Advancing Regenerative Medicine

 

Enhancing Life Through Birth

Enhancing Life Through Birth

Through the development of innovative processing techniques that minimally manipulate the tissue, we are harnessing the unique biologic properties of the placental tissues to improve clinical outcomes.

Unsurpassed Safety and Quality

Unsurpassed Safety and Quality

 Our paramount commitment is to the safety and quality of our products. From aseptic recovery of the tissue at childbirth to timely processing of our allografts, our protocols and procedures have been developed to meet or exceed all applicable industry standards for the use of human cellular and tissue-based products.

The AmnioExcel allograft is a sterile structural tissue that forms a physical barrier around the soft tissue to reduce fibroblast infiltration.  By reducing fibroblast infiltration, the AmnioExCel allograft (1) reduces inflammation at the surgical site; and (2) acts as a structural barrier to preserve the surrounding soft tissue.

Learn More

Amnio-MTM is a structural allograft derived from human amnion. In vivo, amniotic membrane, fluid and cells act as a biologic system whose primary function is to (1) protect the fetus; and (2) aid in fetal growth and development. As a liquid wound covering, Amnio-MTM retains this protective function by acting as a structural matrix for use in filling soft tissue defects or bone voids.

Learn More